Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Novacyt ( (FR:ALNOV) ) just unveiled an announcement.
Novacyt S.A. announced the details of its upcoming Annual General Meeting (AGM) scheduled for June 19, 2025, at the Hilton Hotel near Charles de Gaulle Airport in France. Shareholders are encouraged to vote in advance to meet the quorum requirements for ordinary and extraordinary resolutions. The company has provided multiple voting options, including proxy voting forms, the Votaccess portal, and online voting via brokers or intermediaries. Shareholders can attend the AGM in person if they can prove their shareholding status by the specified deadline. A recording of the AGM will be available on the company’s website after the meeting.
More about Novacyt
Novacyt is an international molecular diagnostics company that provides a broad portfolio of integrated technologies and services, primarily focused on genomic medicine. The company develops, manufactures, and commercializes molecular assays and instrumentation for human health, animal health, and environmental sectors. Novacyt operates through three business segments: Clinical, Instrumentation, and Research Use Only, offering products and services such as in vitro diagnostic products, DNA sample preparation platforms, and qPCR assays. Headquartered in Le Vésinet, France, Novacyt has offices in the UK, Singapore, the US, and Canada, and is listed on the London Stock Exchange’s AIM market and the Paris Stock Exchange Euronext Growth.
See more insights into ALNOV stock on TipRanks’ Stock Analysis page.